Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology